DSKYF (Daiichinkyo Co) Research & Development: $3,068 Mil (TTM As of Mar. 2026)


DSKYF Daiichi Sankyo Co Ltd DSKYF
73 GF Score
Price $14.76
GF Value $40.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Daiichinkyo Co Research & Development?

Daiichinkyo Co DSKYF -4.91% 73 Research & Development is $3,068 Mil as of Mar. 2026. GuruFocus rates DSKYF with a GF Score™ of 73/100 and a GF Value™ of $40.31 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Daiichinkyo Co's Research & Development for the three months ended in Mar. 2026 was $795 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $3,068 Mil.

Daiichinkyo Co  (OTCPK:DSKYF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Daiichinkyo Co Research & Development Related Terms

Daiichinkyo Co Research & Development Historical Data

* Premium members only.

The historical data trend for Daiichinkyo Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co Research & Development Chart

Daiichinkyo Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,195.41 2,555.43 2,437.41 2,924.81 2,936.71

Daiichinkyo Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 894.41 733.30 755.58 783.16 795.46
DSKYF
73GF Score
Daiichi Sankyo Co Ltd DSKYF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daiichinkyo Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,068 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3,068 Mil mean?
Daiichinkyo Co (DSKYF) has a Research & Development of $3,068 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Daiichinkyo Co and its competitors.
Is Daiichinkyo Co's Research & Development too high?
Daiichinkyo Co's current Research & Development is $3,068 Mil. Overall, Daiichinkyo Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Research & Development compare to LLY and JNJ?
Daiichinkyo Co's Research & Development of $3,068 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Daiichinkyo Co and its competitors. Daiichinkyo Co's current Research & Development is $3,068 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $40.31, compared to a current price of $14.76 — trading 63.4% below its estimated fair value. The current Research & Development is $3,068 Mil. Daiichinkyo Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current Research & Development is $3,068 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daiichinkyo Co (DSKYF) Overvalued in 2026?

Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued. The current stock price of $14.76 is trading 63.4% below its estimated GF Value™ of $40.31. GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.

Key valuation signals for DSKYF:

  • Research & Development: $3,068 Mil
  • GF Value™: $40.31 vs. price of $14.76 (63.4% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daiichinkyo Co Business Description

Address 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score

Get the complete analysis for DSKYF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.76
Price
$40.31
GF Value